Evidence map›Paper›PMID 39077632›Full record

ArticleJACC. Advances2024

Interleukin-6 and Cardiovascular Events in Healthy Adults: MESA.

Muhammad Shahzeb Khan, Khawaja M Talha, Muhammad Haisum Maqsood, Jennifer A Rymer, Barry A Borlaug, Kieran F Docherty, Ambarish Pandey, Florian Kahles, Maja Cikes, Carolyn S P Lam and 7 more

Abstract read
In one paragraph

Article in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. The role of IL-6 in atherosclerosis: a narrative review.Frontiers in cardiovascular medicine · 2026
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Muhammad Shahzeb KhanDuke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA.
Khawaja M TalhaDepartment of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Muhammad Haisum MaqsoodDepartment of Cardiology, DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA.
Jennifer A RymerDuke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA.
Barry A BorlaugDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Kieran F DochertyInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Ambarish PandeyDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Florian KahlesDepartment of Internal Medicine I-Cardiology, University Hospital Aachen, Aachen, Germany.
Maja CikesUniversity of Zagreb School of Medicine, University Hospital Centre, Zagreb, Croatia.
Carolyn S P LamDuke-NUS Medical School, Singapore, Singapore.
Anique DucharmeInstitut de Cardiologie, de Montréal, Université de Montréal, Montréal, Québec, Canada.
Adrian A VoorsDepartment of Cardiology, University Medical Center of Groningen, University of Groningen, Groningen, the Netherlands.
Adrian F HernandezDuke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA.
A Michael LincoffHeart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Mark C PetrieInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Paul M RidkerCenter for Cardiovascular Disease Prevention, Division of Preventive Medicine and the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Marat FudimDuke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA.

Funding

Pulmonary Hypertension in Left Heart DiseaseR01HL162828 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug, Margaret M Redfield · 2023 to 2026
$3.1M
HL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection FractionR01HL128526 · NHLBI · MAYO CLINIC ROCHESTER · PI BORLAUG, BARRY A. · 2016 to 2019
$2.4M
Mayo Clinic HeartShare Clinical CenterU01HL160226 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug, Margaret M Redfield · 2021 to 2026
$1.8M
Evaluation of Racial Differences in Cardiorespiratory Fitness Decline with Aging & Underlying Biological MechanismsR03AG067960 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI PANDEY, AMBARISH · 2020 to 2021
$327k
NHLBI NIH HHS R01 HL128526NHLBI NIH HHS R01 HL162828NHLBI NIH HHS U01 HL160226NIA NIH HHS R03 AG067960
6 · The paper itself

Abstract

Background: Elevated interleukin (IL)-6 levels have been linked to adverse outcomes in patients with and without baseline cardiovascular disease (CVD). Objectives: The purpose of this study was to examine the association between circulating IL-6 levels and CVD events without baseline CVD across racial and ethnic groups. Methods: We conducted an observational analysis utilizing the MESA (Multi-Ethnic Study of Atherosclerosis), a multicenter, prospective community-based study of CVD at baseline from four racial and ethnic groups. IL-6 levels were measured at the time of enrollment (visit 1) and were divided into 3 terciles. Patient baseline characteristics and outcomes, including all-cause mortality, CV mortality, heart failure, and non-CV mortality, were included. Cox proportional hazard regression models were used to assess associations between IL-6 levels and study outcomes with IL-6 tercile 1 as reference. Results: Of 6,622 individuals, over half were women (53%) with a median age of 62 (IQR: 53-70) years. Racial and ethnic composition was non-Hispanic White (39%) followed by African American (27%), Hispanic (22%), and Chinese American (12%). Compared to tercile 1, participants with IL-6 tercile 3 had a higher adjusted risk of and all-cause mortality (HR: 1.98 [95% CI: 1.67-2.36]), CV mortality (HR: 1.55 [95% CI: 1.05-2.30]), non-CV mortality (HR: 2.05 [95% CI: 1.65-2.56]), and heart failure (HR: 1.48 [95% CI: 0.99-2.19]). When tested as a continuous variable, higher levels of IL-6 were associated with an increased risk of all individual outcomes. Compared to non-Hispanic White participants, the unadjusted and adjusted risk of all outcomes across all races and ethnicities was similar across all IL-6 terciles. Conclusions: High levels of circulating IL-6 are associated with worse CV outcomes and increased all-cause mortality consistently across all racial and ethnic groups.

Indexed as

cardiovascular diseaseethnicityinflammationinterleukin-6populationrace

Identifiers

PMID39077632
PMCPMC11284704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.